Intermediate hepatocellular carcinoma: current treatments and future perspectives

Area of Science:

• Hepatobiliary Oncology
• Interventional Radiology
• Medical Oncology

Background:

• Transarterial chemoembolization (TACE) is the standard treatment for Barcelona-Clinic Liver Cancer (BCLC)-B stage hepatocellular carcinoma (HCC).
• Long-term survival with TACE is often unsatisfactory, and intermediate-stage HCC encompasses a heterogeneous patient population.
• This heterogeneity suggests not all patients benefit equally from TACE, necessitating exploration of alternative therapies.

Purpose of the Study:

• To review current evidence on locoregional and medical treatments for intermediate-stage HCC.
• To discuss the role of sorafenib as a therapeutic option for BCLC-B patients.
• To explore emerging TACE modalities and radioembolization for HCC management.

Main Methods:

• Narrative review of recent scientific literature.
• Discussion of clinical trial data and treatment guidelines.
• Analysis of locoregional therapies and systemic treatment with sorafenib.

Main Results:

• TACE is standard but has limitations in long-term efficacy for intermediate HCC.
• Alternative TACE techniques (selective, drug-eluting beads) and radioembolization are being investigated.
• Sorafenib provides a new option for BCLC-B patients unsuitable for or intolerant to TACE, with ongoing trials in combination regimens.

Conclusions:

• Treatment decisions for intermediate-stage HCC must consider patient heterogeneity.
• Sorafenib represents a significant advancement for specific BCLC-B patient subgroups.
• Further research into combination therapies and advanced locoregional techniques is crucial for optimizing HCC management.